Hisamitsu Pharmaceutical Company, Inc.

Kumamoto University

Mect Corporation

The Chemo-Sero-Therapeutic Research Institute

Kumamoto Health Science University

National University Corporation Kumamoto University

Kazuo Takahama

Takeshi Miyata

Hiroaki Maeda

Takayuki Ishii

Masaki Hirashima

Takayoshi Hamamoto

Sachio Okuda

Shintaro Kamei

Norio Akaike

Hirofumi Kai

Megumi Imuta

Keiji Komatsu

Chihiro Kibayashi

Hidenao Fukushima

Ryoko Wada

Sachie Ogawa

Misako Umehashi

Asami Shindome

The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as 'FXIa'), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Plasma protein effective for suppressing cough

Medicinal compositions having an effect of regulating the activation of glycine receptor and novel morphan derivatives. Medicinal compositions comprising morphan derivatives or its salts and a pharmaceutically acceptable carrier. These compositions potentiate or inhibit the activation of glycine receptor, which makes them useful as drugs for the central nervous system. Novel 1- and/or 2-substituted morphan derivatives (2-azabicyclo&lsqb;3.3.1&rsqb;nonane derivatives) or salts thereof.

Morphan derivatives or salts thereof and medicinal compositions containing the same

A preparation for treating immune complex diseases which comprises injection containing the following compound: ##STR1## wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, as an active ingredient and pharmacologically acceptable carrier. The preparation of the present invention may be used in any administration method such as hypodermic, intramuscular and intravenous.

Method for treating immune complex diseases with n-acetylneuraminic acid

Growing community of inventors

Kumamoto, Japan

Kazuo Takahama